Publications by authors named "G Mardirossian"
CyberKnife SBRT is capable of producing dosimetry comparable to that created by HDR brachytherapy. Our original CyberKnife prostate SBRT schedule of 3,800 cGy/4 fractions ("high dose") was based upon favorable published prostate HDR brachytherapy experience. Subsequently, our trial was modified to allow a lower dose of 3,400 cGy/5 fractions ("moderate dose") in selected cases.
View Article and Find Full Text PDFPurpose: Some studies have suggested that the presence of a static magnetic field (SMF) during irradiation alters biological damage. Since MRI-guided radiotherapy is becoming increasingly common, we constructed a DNA-based detector to assess the effect of a 1.5 T SMF on DNA damage during high dose rate (HDR) brachytherapy irradiation.
View Article and Find Full Text PDFPurpose: We evaluated the use of high dose-rate-like stereotactic body radiation therapy (SBRT) retreatment for biopsy-proven local persistence in prostate postradiation therapy, evaluating efficacy and toxicity.
Methods And Materials: From 2009 to 2018, 50 patients with biopsy-proven recurrent prostate cancer >2 years after prior treatment were retreated with a high dose-rate-like dose of 3400 cGy over 5 fractions. Previous radiation therapy dose measured 75.
Purpose: The impact of higher scatter doses per fraction on testicular function and quality of life after prostate stereotactic body radiation therapy (SBRT) is poorly studied.
Methods And Materials: Six hundred thirty-six patients treated with SBRT for low- to intermediate-risk prostate cancer from 2009 to 2014 were included. Changes in testosterone and in sexual and hormonal domain scores on the Expanded Prostate Cancer Index Composite-26 (EPIC) questionnaire over a 24-month period were evaluated via a 1-sided t test.
Article Synopsis
- This study examined the effectiveness of high-dose-rate-like stereotactic body radiation therapy (SBRT) for patients with locally recurrent prostate cancer after previous radiation treatment.
- The research involved 29 patients, revealing significant reductions in prostate-specific antigen levels and a promising 82% two-year biochemical disease-free survival rate, with no local cancer recurrences reported.
- While some patients experienced grade 2 or higher genitourinary side effects, there were no severe gastrointestinal issues, indicating the treatment's overall safety profile is relatively favorable.